Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab plus Chemotherapy in Recurrent/Metastatic HNSCC
NCT04361409Phase 1Completed
- Sponsor
- China Medical University Hospital
- Start
- May 2013
- Primary completion
- Nov 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rituximab in head and neck squamous cell carcinoma (HNSCC), sponsored by China Medical University Hospital. Primary endpoint: Feasibility of the combination. Started May 2013; status: completed.
02
Drugs
rituximab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04361409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04361409.